Table A2.
Outcome to Treatment With EGFR Tyrosine Kinase Inhibitors Erlotinib and Gefitinib in Glioblastoma
| Study by Treatment Agent | No. of Patients | Outcome Measure |
||
|---|---|---|---|---|
| Response Rate (%) | MTP (weeks) | 6-Month PFS (%) | ||
| Gefitinib | ||||
| Rich22 | 53 | NA | 8.1 | 13 |
| Lieberman* | 38 | 13 | 8 | 9 |
| Erlotinib | ||||
| Vogelbaum11 | 31 | 6 | NS | 26 |
| Raizer† | 31 | 0 | 12 | 0 |
| Cloughesy‡ | 48 | 8 | NS | 17 |
Abbreviations: EGFR, epidermal growth factor receptor; MTP, median time to progression; PFS, progression-free survival; NA, not applicable; NS, not stated.
*
Lieberman FS, Cloughesy T, Malkin MG: J Clin Oncol 22:105, 2003 (abstr 421).
†
Raizer JJ, Abrey LE, Wen P, et al: J Clin Oncol 40:107, 2004 (abstr 1502).
‡
Cloughesy T, Yung A, Vrendenberg J, et al: J Clin Oncol 41:115s, 2005 (abstr 1507).